MeadeT.W.Thrombosis and ischemic heart disease.Br Heart J1985; 53: 473–6.
2.
SkartlienA.H., Lyberg-BeckmannS., HolmeI., HjermannI., PrydzH.Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma.Arteriosclerosis1989; 9: 798–801.
3.
Juhan-VagueI., AlessiM.C., VagueP.Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.Diabetologia1991; 34: 457–62.
4.
AthyrosV.G., PapageorgiouA.A., AvramidisM.J., KontopoulosA.G.Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.Coron Artery Dis1995; 6: 251–6.
5.
AndersenP., SmithP., SeljeflotI., BratakerS., ArnesenH.Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.Thromb Haemost1990; 63: 174–7.
6.
IrishA.B., ThompsonC.H.The effects of gemfibrozil upon the hypercoagulable state in dyslipidemic patients with chronic renal failure.Nephrol Dial Transplant1996; 11: 2223–8.
7.
AkcicekF., OkE., DumanS., KursadS., UnsalA., AlevM.Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: A prospective cross-over study. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1996; 12: 261–5.
8.
SamuelssonO., AttmanP.O., Knight-GibsonC., KronB., LarssonR., MulecH.Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: A controlled study in human chronic renal disease.Nephron1997; 75: 286–94.
9.
BrownerW.S., BlackD., NewmanT.B., HulleyS.B.Estimating sample size and power. In: HulleyS.B., CummingS.R., eds. Designing clinical research.Baltimore: Williams & Wilkins, 1988; Chap 13: 139–50.
10.
KimS.B., YangW.S., LeeS.K., ChiH.S., ParkJ.S.Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients.Nephrol Dial Transplant1998; 13: 2053–8.
11.
BlannA.D., JacksonP., BathP.M., WattsG.F.Von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet.J Intern Med1995; 237: 557–61.
12.
ElisafM.S., DardamanisM.A., PapagalanisN.D., SiamopoulosK.C.Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.Scand J Urol Nephrol1993; 27: 101–8.
13.
GaultM.H., LongerichL.L., PurchaseL., HarnettJ., BreckenridgeC.Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.Nephron1995; 70: 155–70.
14.
SchlechteJ.A., KreisbergR.Update in endocrinology.Ann Intern Med1998; 129: 719–25.
